Assessment of Combined CCM and ICD Device in HFrEF

Not Applicable

Active, not recruiting

• Conditions: Heart Failure; Heart Failure With Reduced Ejection Fraction; Implantable Defibrillator User; CCM Therapy; Non-ischemic Cardiomyopathy; Ischemic Cardiomyopathy; Sudden Cardiac Arrest; Arrhythmias, Cardiac; Ventricular Tachycardia; Ventricular Fibrillation

• Registration Number: NCT05855135
• Lead Sponsor: Impulse Dynamics

Brief Summary

The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).

Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-03
• Study First Submitted QC: 2023-05-03
• Study First Posted: 2023-05-11
• Study Start: 2023-05-17
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-28
• Last Update Posted: 2025-07-31
• Primary Completion: 2026-01
• Study Completion: 2027-07-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Individuals must meet all the following:

1. Patient is aged 18 years or older;
2. Patient meets the Stage C or D criteria of the Universal Definition of Heart Failure ;
3. Patient has HFrEF (LVEF ≤40%);
4. Patient is on GDMT for heart failure;
5. Patient has a Class I or Class II indication for an ICD
6. Patient has a reasonable expectation of meaningful survival of > 1 year;
7. Patient has either non-ischemic cardiomyopathy or ischemic cardiomyopathy and is at least 40 days post-MI, if an MI occurred;
8. Patient is willing to give informed consent, available for scheduled study follow-up visits, and able to complete all testing described in the study protocol at the investigational site location.

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Patients should not have severe AI or AS, and should not have MS; additionally, patients undergoing DE testing should not have severe MR;
2. Patients who have undergone mitral valve repair or clip within 90 days prior to study consent;
3. Cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;
4. Prior heart transplant or ventricular assist device;
5. Implanted mechanical tricuspid valve;
6. PR interval greater than 375ms or advanced AV block;
7. In situ S-ICD, pacemaker, or CRT device;
8. Indicated for CRT;
9. End stage renal disease, currently on dialysis, or with other major medical disorder (e.g. liver failure, terminal cancer);
10. Indicated for permanent bradyarrhythmia pacing;
11. Unstable angina pectoris within 30 days prior to study consent;
12. Pregnant or planning to become pregnant during the study;
13. Participating in another cardiac investigational device or drug study at the same time (or within 30 days prior to study consent); Note: Registries and other observational studies are acceptable.
14. Other criteria that preclude Optimizer INTEGRA CCM-D implantation and/or CCM therapy, as determined by Investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Device-related Complications (Primary Safety Objective)	Implant to 6 months	Evaluate device-related complications through 6-months (excluding lead-related complications).
Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)	Implant	Evaluate the device effectiveness in converting induced VF at the time of implantation.

Secondary Outcome Measures

Name	Time	Method
Inappropriate Shock Rate out to 6-months (Secondary Safety Objective)	Implant to 6 months	Evaluate the incidence of inappropriate ICD shocks through the time when the last subject enrolled completes the 6-month visit.

Trial Locations

Locations (58)

Phoenix Heart; 🇺🇸 Phoenix, Arizona, United States

CardioVascular Associates of Mesa; 🇺🇸 Mesa, Arizona, United States

Southwest Cardiovascular Associates; 🇺🇸 Mesa, Arizona, United States

Arizona Heart Rhythm; 🇺🇸 Phoenix, Arizona, United States

CVC Cardiovascular Consultants; 🇺🇸 Phoenix, Arizona, United States

Honor Health; 🇺🇸 Scottsdale, Arizona, United States

University of Southern California; 🇺🇸 Los Angeles, California, United States

Cedars Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Aurora Denver Cardiology Associates; 🇺🇸 Aurora, Colorado, United States

Hartford HealthCare; 🇺🇸 Hartford, Connecticut, United States

Scroll for more (48 remaining)